The highly specialized human brain microvascular endothelium forms a selective blood-brain barrier (BBB) with adjacent pericytes and astrocytes that restricts delivery of many pharmaceuticals and therapeutic antibodies to the central nervous system. Here, we describe an in vitro microfluidic 'organ-on-achip' (Organ Chip) model of the BBB lined by induced pluripotent stem cellderived human brain microvascular endothelium (iPS-BMVEC) interfaced with primary human brain astrocytes and pericytes that recapitulates the high level of barrier function of the in vivo human BBB for at least one week in culture. The endothelium expresses high levels of tight junction proteins, multiple functional efflux pumps, and displays selective transcytosis of peptides and anti-transferrin receptor antibodies previously observed in vivo. This increased level of barrier functionality was accomplished using a developmentally-inspired induction protocol that includes a period of differentiation under hypoxic conditions. This enhanced BBB Chip may therefore represent a new in vitro tool for development and validation of delivery systems that transport drugs and therapeutic antibodies across the human BBB.
However, the usefulness of these iPS-BMVEC models for studies on targeted delivery to the CNS is limited because they can only maintain these high TEER levels for ~2 days, and the expression of efflux pumps in these iPS-BMVECs does not fully mimic those of human brain endothelium in vivo 21 . Here, we describe the development of an enhanced human BBB model created with microfluidic Organ Chip culture technology 22, 23 that contains human iPS-BMVECs interfaced with primary human pericytes and astrocytes, and that uses a developmentally-inspired differentiation protocol [24] [25] [26] . The resulting human BBB Chip exhibits physiologically relevant levels of human BBB function for at least one week in vitro, including low barrier permeability and expression of multiple efflux pumps and transporter functions that are required for analysis of drug and therapeutic antibody transport.
RESULTS

Developmentally-inspired enhancement of brain endothelium differentiation
Given that the BBB first forms in the developing brain in a relatively oxygen-poor environment (1%-8%) before establishment of the circulatory system 24 , and oxygen availability has been shown to play a vital role in endothelial differentiation from a variety of stem cell sources [25] [26] [27] , we hypothesized that culturing iPS cells under similar hypoxic conditions could generate more highly differentiated BMVECs and potentially stabilize their phenotype. The published differentiation induction protocol for creating human BMVECs involves culture of iPS cells on Matrigel for 3 days in mTeSR1 medium followed by 6 days in DMEM-F12 medium, and then 3 days in endothelial cell medium containing retinoic acid under normoxic (20% O2) conditions 15 . Thus, to explore this possibility, we modified this method for inducing differentiation of BMVECs from human iPS cells by shifting the cultures to hypoxic conditions (5% O2) for the last 9 days of the induction protocol ( Supplementary Fig. S1a ). Importantly, we found that exposure to hypoxia during this differentiation protocol produced significant (2-to 6-fold) increases in the mRNA levels for the endothelial cell-cell adhesion molecules, VE-cadherin (vascular endothelial cadherin) and PECAM-1 (platelet endothelial cell adhesion molecule, also known as CD31), as well as the influx transporter GLUT-1 (BBB-specific glucose transporter), efflux transporter P-gp (permeability glycoprotein), and VEGF-A (angiogenic vascular endothelial growth factor-A), relative to control iPS-BMVECs induced under normoxic conditions (Supplementary Fig. S1b ). The increased expression of these endothelial molecules that play an essential role in CNS neovascularization [28] [29] [30] confirmed the successful transition of the iPS cells into a human BMVEC phenotype.
Canonical Wnt/b-catenin signaling is essential for development of brain microvessels, and Wnt ligands Wnt7a and Wnt7b have been implicated in BBB development in vivo 18, 31 . We similarly found that Wnt7a mRNA levels increased by over 25-fold with the hypoxic induction protocol compared to normoxic conditions, while Wnt7b levels remained unchanged (Supplementary Fig. S1c ). In addition, past in vitro and in vivo studies showed that Wnt/b-catenin signaling pathways interplay with hypoxia-induced factor 1a (HIF1a) signaling 32, 33 . Indeed, ELISA analysis revealed that HIF1a protein levels were upregulated by exposure to hypoxia during the differentiation protocol; however, they decreased when the differentiation was completed and the cells shifted to normoxic conditions after seeding on-chip (Supplementary Fig. S1d) .
Interestingly, we found that we could produce similar results by exposing the iPS cells to 100 µM cobalt chloride (CoCl2) for the same 9 day period while under normoxic conditions ( Supplementary Fig. S1d ); CoCl2 has been previously shown to chemically mimic the effects of hypoxia by stabilizing HIF1a 34 . This finding may obviate the need for specialized gases and culture chambers for induction of improved BMVEC differentiation in future studies.
On-chip reconstitution of a functional human BBB under oxygen control
To explore whether these hypoxia-induced iPS-BMVECs could be used to build a human BBB Chip with enhanced functionality, we used soft lithography to create optically clear, poly(dimethylsiloxane) (PDMS), 2-channel, microfluidic devices containing an upper CNS microchannel separated from a parallel vascular microchannel by a porous (2 µm diameter), polyethylene terephthalate (PET) membrane coated on both sides with an ECM composed of collagen type IV and fibronectin ( Fig. 1a) . A mixture of primary human brain astrocytes and pericytes (seeding ratio of 7:3) were then cultured in the astrocyte medium on the PET membrane in the upper channel under static conditions for 1 hour. Human iPS-BMVECs cultured for 8 days under hypoxic (5% O2) conditions on Matrigel were removed using Accutase and plated on the bottom surface of the ECM-coated porous membrane in the lower channel of the microfluidic chip in endothelial medium with addition of retinoic acid using similar culture conditions and flow rate. Chips were flipped and incubated for 5 hours to induce adhesion of iPS-BMVECs to the membrane. The BBB Chip was cultured for 1 additional day under hypoxia to promote endothelial monolayer formation and to acclimate the cells to the device before being shifted to normoxic conditions for the remainder of the experiment and before initiating continuous medium flow (100 µL/h) ( Fig. 1b) . We also controlled flow through the vascular channel to maintain physiological levels of fluid shear stress (6 dyne/cm 2 at 100 µL/h) and a blood-like viscosity (3-4 cP; modified by adding 3.5% dextran to the medium).
Confocal immunofluorescence microscopic analysis after 3 days of microfluidic culture revealed that these conditions resulted in formation of an iPS-BMVEC monolayer that covered all four walls of the lower channel, creating a hollow vascular lumen, in addition to being interfaced directly across the porous ECM-coated membrane with primary human pericytes and astrocytes in the CNS channel above ( Fig. 1a , Supplementary Video 1). Higher magnification views revealed that the astrocytes extended processes through the 2 µm pores of the PET membrane, and thus, came into direct contact with the luminal surface of the brain endothelium below (Supplementary Video 2). These hypoxia-induced iPS-BMVECs also formed well developed tight junctions containing ZO-1 and Claudin-5, and expressed high levels of the cell-cell adhesion protein PECAM-1 along their lateral borders, as well as GLUT1 and P-gp transporters on their apical cell membrane ( Fig. 1c) . Electron microscopic analysis confirmed that the differentiated iPS-BMVEC monolayer also displayed well developed tight junctions and adherens junctions with characteristic morphology along the membrane-membrane interfaces between adjacent endothelial cells ( Fig. 1d ). Under these flow conditions, the endothelial monolayer within the human BBB Chip maintained its tight junctional integrity and continued to express high levels of ZO-1 as well as the glucose transporter GLUT-1 -the major nonneuronal glucose transporter in brain -on their apical surface for at least one week in culture, as detected by immunofluorescence microscopy (Fig. 1e) .
Hypoxia-induced enhancement of brain-specific endothelial cell differentiation was also observed when gene and protein expression levels of representative BBB markers were compared in iPS-BMVECs cultured on-chip differentiated under hypoxic versus normoxic conditions. Statistically significant increases in mRNA expression were observed for genes encoding GLUT1, insulin receptor protein (INSR), and the BBB efflux transport proteins P-gp, BCRP (breast cancer resistant protein), and multidrug resistance proteins 1 and 4 (MRP1 and MRP4), as well as endothelial cell-specific VEcadherin ( Supplementary Fig. S2a ). Increases in P-gp and BCRP expression were also confirmed by Western blot analysis ( Supplementary Fig. S2b ). Moreover, mass spectrometric (MS) analysis of iPS-BMVECs collected from BBB Chips on the 3 rd day of seeding revealed higher protein levels of ATP-binding cassette (ABC) and solute carrier (SLC) transporter proteins in hypoxia-differentiated brain endothelium cultured in the BBB Chips compared to endothelium differentiated under normoxic conditions ( Fig. 2a,   Supplementary Fig. S3 ). These results are similar to those from previous proteomic studies that also demonstrated enrichment of BCRP1, MRP1, and MRP4 proteins in the BBB relative to other microvessels in animal studies 35 . Furthermore, to determine the contribution of astrocytes and pericytes to the function of iPS-derived human brain microvascular endothelium, we compared the mRNA profiles of iPS-BMVECs in monoculture versus co-culture under continuous flow in the microfluidic BBB Chip. The mRNA levels of INSR, VE-cadherin, MRP1, and ZO-1 were all significantly higher in iPS-derived microvascular endothelium when co-cultured with brain astrocytes and pericytes on-chip ( Supplementary Fig. S4 ).
Reconstitution of in vivo levels of barrier function in the human BBB Chip
Importantly, the higher expression of BMVEC-specific surface markers we observed in the presence of pericytes and astrocytes ( Fig. 1, Supplementary Fig. S4) was associated with enhanced barrier function, as quantified by measuring TEER onchip using BBB Chips that contained integrated electrodes 36, 37 . This method generates results as impedance in Ohms (Ω) rather than resistance (Ω·cm 2 ) because it is not normalized for surface area. These studies revealed that the impedance values of BBB Chips created with iPS-BMVECs differentiated under hypoxic conditions along with astrocytes and pericytes were ~25,000 Ω ( Fig. 2b) , which is 2 orders of magnitude higher than levels previously reported for BBB chips containing primary human BMVECs along with the brain perivascular cells (~400 Ω) ( Supplementary Fig. S5 ). In contrast, while chips containing iPS-BMVECs established under normoxic conditions displayed a similar high maximum impedance value of ~24,000 Ω at 2 days after plating, barrier levels dropped by more than 50% by day 3, and by greater than 80% at one week ( Fig. 2b) . These latter results were nearly identical to those previously reported by others who cultured iPS-BMVECs established under normoxic conditions in either Transwell inserts or Organ Chip devices 15, 39, 40 . We independently confirmed these results using fluorescently labelled dextran tracers to measure barrier integrity.
The apparent permeability (Papp) of the BBB Chip lined by hypoxia-induced iPS-BMVECs, astrocytes and pericytes was very low (~10 -8 -10 -9 cm/s), and the Papp value inversely correlated with the size of the tracer (average Papp = ~8.9, 1.1, and 0.24 x 10 -8 cm/s for 3,10, and 70 kDa dextrans, respectively) ( Supplementary Fig. S6 ), as previously demonstrated in vitro and in vivo [39] [40] [41] . It is important to note that fluid flow also appeared to be required to sustain barrier function over time as we did not observe this level of barrier development when the same hypoxia-induced BMVECs were interfaced with astrocytes and pericytes cells in static Transwell cultures ( Fig. 2c) .
Furthermore, when we treated BBB Chips lined with iPS-BMVECs differentiated under normoxic conditions with the HIF1a inducer CoCl2 (100 µM), we produced nearly identical enhancement of TEER and similar results were obtained with another chemical hypoxia mimetic, dimethyloxalylglycine (DMOG; 100 µM) ( Supplementary Fig. S7 ).
The highly enhanced, in vivo-like level of barrier function (>20,000 Ω) obtained with iPSderived hBMVECs differentiated using CoCl2 also could be prolonged for more than 2 weeks when cultured under continuous flow in the microfluidic BBB Chip ( Supplementary Fig. S8a ). In contrast, this high level of barrier function again was not obtained when the same cells were interfaced with astrocytes and pericytes under static conditions in Transwell cultures ( Supplementary Fig. S8b ). Confocal immunofluorescence microscopic analysis of the CoCl2-activated human BBB Chips also confirmed that high levels of expression of ZO-1 and GLUT-1 were sustained on the surface of the iPS-BMVECs in these cultures ( Supplementary Fig. S9 ).
Utility for studying molecular trafficking across the human BBB in vitro
Next, we tested if the enhanced human BBB Chip containing hypoxiadifferentiated iPS-BMVECs, astrocytes and pericytes can recreate a functional metabolic barrier that regulates molecular traffic across the BBB, and if this occurs in a more physiologically relevant manner than in chips containing cells differentiated under normoxic conditions. The array of ABC transporters in the BBB, which includes P-gp, MRP1 & 4, and BCRP, provides an important defense mechanism that actively secretes molecules leaked out of blood back into the capillary lumen in order to protect the brain 42, 43 . As we found that all of these ABC efflux pumps are expressed on the apical surface of the human iPS-BMVECs induced by hypoxia ( Fig. 1c, Fig. 2a ), we next analyzed their functionality and substrate selectivity. The hypoxia induction method was used for this and all subsequent studies because small molecule inducers may not mimic all of the effects of the hypoxic environment 44, 45 , and thus, their use would require further system characterization.
To assess P-gp activity in the BBB Chip, we pretreated the chips with the P-gp inhibitor, verapamil, and then the known P-gp substrates, rhodamine 123 and DiOC2 46 as well as the drug citalopram, were perfused through the endothelium-lined vascular channel of the BBB Chips. Transcytosis of the P-gp substrate molecules with and without P-gp inhibitor treatment were measured under continuous flow conditions. The Papp of rhodamine 123 and DiOC2 were calculated by measuring changes in their fluorescent intensities between the two channels; MS analysis was used to measure the permeability of citalopram.
These studied revealed significant enhancement of the permeability of all three of these molecules through the BBB on-chip when the P-gp efflux pump was blocked by its inhibitor, verapamil, whereas a significant increase in the permeability of these molecules could not be detected when the same cells were interfaced to form a BBB in static Transwell cultures ( Fig. 3a) . Remarkably, citalopram was also shown to increase its permeability when P-gp was inhibited in the microfluidic BBB Chip (Fig. 3a) , which recapitulates similar in vivo findings shown in past animal studies [47] [48] [49] [50] . This is an important result because all past in vitro BBB models failed to identify citalopram as a Pgp substrate 51, 52 .
To analyze the activities of BCRP and MRP1 transporter proteins, the BBB Chips were pretreated with inhibitors of various ABC transporter inhibitors, including verapamil MK571, and Ko143 that target P-gp, the MRPs and BCRP, respectively, and then uptake of fluorescent substrates, rhodamine 123 and DiOC2, was quantified under flow using fluorescent dextran (3 kDa) to monitor barrier integrity. When we measured the Papp of these two ABC transporter substrates in BBB Chips containing iPS-BMVECs differentiated under hypoxic conditions along with astrocytes and pericytes, we found that inhibition of P-gp with verapamil resulted in significant influx of rhodamine 123 and DiOC2 into the CNS channel, and inhibition of BCRP with Ko143 had a small but significant effect on transport of DiOC2, but no effect on rhodamine 123, as previously described in other models 15, 53 (Fig. 3b) . In contrast, when similar studies were carried out with BBB Chips generated under normoxic conditions, we observed an increase of rhodamine 123 in the CNS channel when MRP1 was inhibited, but no change when Pgp was inhibited, and DiOC2 influx was not affected by any of the inhibitors (Fig. 3b) .
As P-gp is the main efflux pump for rhodamine 123 54, 55 and DiOC2 influx was modulated in a manner similar to what is observed in vivo 54 in the hypoxic chips, these studies demonstrate that while the iPS-BMVECs differentiated under normoxic conditions may generate an effective permeability barrier 15,56 , they do not fully recapitulate the human BBB's specialized molecular transport functions that are highly relevant to the drug development process.
To further investigate the potential of the hypoxia-induced human BBB Chip as an in vitro tool to study brain transporter-dependent drug efflux, we tested the cancer drug doxorubicin (Dox). While Dox is used to treat many types of cancer, its efficacy for brain tumors is limited due to poor penetration of the drug through the BBB because it is pumped back out of the endothelium and into the blood predominantly by P-gp transporters 57 , and less by MRP1 58 or BCRP 59 . Consistent with these in vivo observations in humans, we found that inhibition of P-gp with Verapamil induced more than a 2.7-fold increase in Dox influx into the CNS channel (rise in Papp from 1.4 to 3.7×10 -8 cm/s) when added under flow (100 µL/h) through the vascular channel of the BBB Chip ( Fig. 3c) , which is similar to the P-gp efflux ratio observed in vivo 43 . Again, as observed in vivo, inhibition of MRP1 or BCRP did not alter the permeation of Dox into the CNS channel ( Fig. 3c) . Together, these results suggest that differentiation of iPS-BMVECs in the presence of hypoxia, and positioning of these cells under physiological flow at a tissue-tissue interface with human brain pericytes and astrocytes, generates of an artificial human BBB that exhibits higher substrate specificity and functionality of the efflux barrier than previously reported in any in vitro BBB model.
Reversible osmotic opening of the human BBB on-chip
Hyperosmolar agents, such as high concentration mannitol solutions, are used clinically to overcome the BBB permeability limitation in order to increase delivery of drugs to the brain 60, 61 . Intravenous infusion of a mannitol solution induces reversible opening of pores within the BBB with a radius of about 200Å in animals 60, 62 and humans 62, 63 , and this recovers due to bulk fluid flow from the blood to the brain 63 . We therefore explored whether we can use our hypoxia-enhanced BBB Chip to model delivery of large antibodies, such as those used as cancer therapeutics, by opening the barrier with hypertonic mannitol on-chip. Hypertonic (485 mOsmol/L) mannitol solution was flowed through the endothelium-lined vascular channel of the BBB Chip for 1 hour to open the BBB, and then additional hypertonic medium containing 10 kDa dextran and the anti-cancer therapeutic antibody, cetuximab, was flowed for an additional hour through the same channel (Fig. 4a) .
Constant exposure to the hypertonic medium resulted in a 50% drop in TEER within 2 hours, which gradually recovered to normal levels within 4 hours following infusion of isotonic medium into the vascular channel ( Fig. 4b) . Osmotic opening of the BBB in this manner also resulted in increased penetration of both 10 kDa dextran ( Fig.   4c ) and the cetuximab antibody ( Fig. 4d) into the CNS channel, as measured by a rise in Papp from 3 to 32×10 -8 cm/s and from 2 to 5.1×10 -8 cm/s, respectively. The hypertonic medium was replaced by isotonic medium containing the same compounds after 1 hour to allow the BBB Chip to recover barrier function, and after an additional 30 mins, we found that the barrier integrity measured by TEER had not fully recovered ( Fig. 4b) ,
indicating that both the dextran and the antibody continued to penetrate through the BBB and into the CNS channel. However, the permeabilities of dextran ( Fig. 4c ) and the antibody (Fig. 4d) decreased to the normal range within 4 hours, resulting in full recovery of barrier integrity (Fig. 4b) . To our knowledge, this is the first demonstration of delivery of a clinically approved antibody drug by reversible osmotic opening of the human BBB in vitro, which mimics responses seen in human patients [61] [62] [63] .
The BBB prevents the transport of nearly 100% of large drugs (>500 Da) and antibodies (150 kDa) into the brain, and thus, many laboratories are seeking ways to discover new brain-targeting molecules that could enable delivery of drugs across the BBB and into the CNS. A few brain shuttling molecules have been identified, including IgG antibodies 64 and ligands for cell surface receptors on the brain microvascular endothelium that help drugs transit through the endothelium and into the CNS via receptor-mediated transcytosis 65 . Accurate in vitro assessment of CNS-targeted drug delivery has not been possible previously because it requires that human BBB culture models provide a physiological barrier that prevents paracellular leakage, as well as expression of brain endothelial cell-specific receptors and transporters. Given the high level of differentiation of iPS-BMVECs in our hypoxia-induced human BBB Chip, we explored whether this improved model can be used to directly assess the human BBB penetrating capacity of peptides, nanoparticles, and antibodies in vitro.
Angiopep-2 is a small peptide ligand of LRP-1 that has been shown to penetrate the BBB in vitro and in vivo 66 . The brain penetrating capacity of multiple drugs, including paclitaxel 67,68 and a cancer therapeutic HER-2 antibody 69 , has been shown to be enhanced when modified with Angiopep-2. When we flowed Qdot nanoparticles (20 nm) coated with Angiopep-2 through the endothelium-lined vascular channel of the human BBB Chip, these particles exhibited >200-fold greater capacity to penetrate into the CNS channel compared to uncoated Qdots (Fig. 5a) , even though there was no significant change in barrier integrity (Supplementary Fig. S10a) .
The transferrin receptor (TfR) on BMVECs also has been shown to function as a molecular shuttle that can mediate differential penetration of anti-TfR antibodies through the BBB that differ in their binding affinity. More specifically, the anti-TfR antibody MEM-75 has been shown to penetrate into the brain more efficiently than the 13E4 antibody in vitro 70 . This is because MEM75 has a reduced affinity for the receptor at pH 5.5, while the 13E4 anti-TfR antibody exhibits a pH-independent affinity that results in its entrapment within intracellular vesicles in brain endothelial cells. In past studies with in vitro human BBB models, including studies with human iPS-BMVECs in Transwell cultures, it was not possible to replicate this highly clinically relevant form of shuttling across the BBB because of the poor barrier function and high levels of para-cellular influx 70, 71 , and we obtained similar results when MEM75 or 13E4 antibodies were flowed through the vascular channel with the BBB Chip containing endothelium differentiated under normoxic conditions (Fig. 5b) . We also did not observe any significant difference in transcytosis ability between these two TfR antibodies when we flowed the antibodies through BBB Chips lined by primary (as opposed to iPSC-derived) human BMVECs ( Supplementary Fig. S11) , which produced only a minimal (~1.4-fold) difference in transcytosis abilities for the two TfR antibodies much as previously observed in past microfluidic primary BBB models 72 . In contrast, when these anti-TfR antibodies were flowed through the vascular channel of the hypoxia-enhanced BBB Chip, we were able to demonstrate the 3-fold higher penetrance of MEM-75 into the CNS channel relative to the 13E4 antibodies that was previously predicted in vitro 70 (Fig. 5b) , and this was accomplished without compromising general barrier integrity (Supplementary Fig.   S10b ). In addition, BBB Chips formed with iPS-BMVECs induced by exposure to CoCl2 exhibited similar differential transcellular transport, again capturing the 3-fold difference between the two anti-TFR antibodies (Fig. 5b) without disrupting barrier integrity ( Supplementary Fig. S10c ).
DISCUSSION
Taken together, these results demonstrate that mimicking the hypoxic microenvironment of the developing brain during differentiation of human iPSCs into BMVECs, by either lowering oxygen levels or adding HIF1a-inducing mimetics (e.g., The human BBB Chip containing human iPS-BMVEC differentiated under developmentally-inspired hypoxic conditions exhibited greatly increased and sustained barrier function than past in vitro BBB models with TEER levels similar to those estimated for the human BBB in vivo 73 . Moreover, this enhanced induction of brainspecific endothelial cell differentiation by hypoxia is mediated by HIF1a, and the hypoxia conditioning step can be circumvented by artificially increasing HIF1a levels using small molecules (CoCl2 or DMOG) that have been previously shown to mimic the effects of hypoxia under normoxic conditions 34, 74 .
We and others have previously developed 3D human BBB Chip models using immortalized, primary, or iPS-derived BMVECs, but they either fail to generate in vivolike barrier function or rapidly lose their phenotypic properties 6, 15, 28, 75, 76 . Another microfluidic BBB Chip was developed as a potential tool for drug testing that contains human iPS-BMVECs derived under normoxic conditions and cultured under continuous flow 41 ; however, those cells were interfaced with rat (rather than human) astrocytes, there were no pericytes in that model, and active barrier function specifically mediated by active efflux pumps was not fully assessed. Another microfluidic BBB model was developed utilizing iPS-BMVECs that provides a tight barrier function for up to 6 days 77 , but this model only contains a single microfluidic channel, which makes it difficult to carry out TEER measurements, explore the contributions of parenchymal cells, or test for the transcytotic delivery of different drugs. The advantage of the hypoxia-enhanced BBB Chip is that it sustains in vivo-like barrier functions for much longer periods of time (at least 2 weeks) as well as tightly regulated transcellular transport activities that are crucial for drug development studies, while providing direct access to both the parenchymal and vascular compartments. Hence, it should provide a more accurate model for assessing the ability of chemicals, CNS therapeutics, and drug targeting vehicles to pass through the human BBB and enter the brain.
The enhanced differentiation conditions we applied were inspired by the observation that the BBB forms in a hypoxic environment during embryological development 27, 44, 78 , and this is accompanied by expression of Wnt7a/Wnt7b 29,31 , as well as HIF1a 79 . Interestingly, when we differentiated the human iPSCs under similar hypoxic conditions, they expressed a similar developmental program including expression of Wnt7a and HIF1a, indicating that hypoxia triggers these changes in vitro as well. Importantly, this response was also accompanied by upregulation of various biomarkers associated with brain neovascularization including VEGF, GLUT1, VEcadherin, and PECAM, as well as improved formation of cell-cell junctions and membrane transporters that resulted in significantly improved BBB function that was stable over longer times than observed in past models. But induction of HIF1a appears to be the essential trigger for the generation of an enhanced in vivo-like BBB Chip as similar induction of iPS-BMVEC differentiation could be obtained by addition of small molecule inducers of HIF1a (CoCl2 and DMOG). In fact, treatment with these hypoxia mimetics may prove to be a useful method to generate improved iPSC-derived BBB Chips without requiring a specialized hypoxic chamber. It is also interesting to note that this hypoxia-induced differentiation response appears to be specific for the human iPSCs as exposure to human primary adult BMVECs to hypoxia results in the opposite response (e.g., increased levels of HIF1a induce expression of VEGF, which leads to higher BBB permeability and edema) 80, 81 . In contrast, in the hypoxia-induced iPS-BMVECs, this response was not observed likely because HIF1a levels decreased drastically when the differentiated hBMVECs were seeded in the chip.
Using the hypoxia-enhanced human BBB Chip, we were able to demonstrate that many clinically relevant responses of the BBB can be recapitulated in vitro. The first and most important is maintenance of sustained levels of low barrier permeability similar to those observed in human brain for more than 2 weeks in vitro. We also showed that the BBB Chip can be used to study reversible opening of the BBB using hypertonic solutions in vitro, as is done in vivo; this technique may be used to develop improved therapeutic delivery strategies in the future, as demonstrated here by delivery of an FDA approved therapeutic antibody, mimicking a clinically relevant drug delivery strategy 61 .
Even more importantly, the enhanced BBB chip was able to mimic transporter-mediated drug efflux including appropriate substrate specificity. Using our enhanced BBB Chip, we first recapitulated in vivo interaction of P-gp and citalopram [47] [48] [49] [50] for 20 minutes at room temperature to bond silanes to the surface of the parts. Parts were rinsed in MilliQ filtered water and dried with compressed air. Parts were aligned and bonded by hand and placed in a 60°C oven under 500 g weights for at least 12 hours to anneal the bond. Chips were inspected for delamination, debris, or other defects before use.
BBB reconstitution on a chip. PDMS surface of the chips were activated with oxygen plasma treatment and the channels were coated with collagen IV (400 µg/ml) and fibronectin (100 µg/ml) overnight. Both channels of the chip were rinsed with PBS and then with astrocyte media before seeding cells. For coculturing astrocytes and pericytes in the brain channel of the BBB Chip, a density of 0.7×10 6 cells/ml of human astrocyte and 0.3×10 6 cells/ml of pericyte were mixed together in the astrocyte media and seeded on the apical channel of the chip, then incubated at in the incubator for 1 h. To remove the access of the astrocyte and pericytes, channels of the chip were washed with EC+RA medium (endothelial medium with addition of fibroblast growth factor (Fgf) and retinoic acid (RA) 38 ) and then 23×10 6 cells/ml of iPS-BMVEC (D8) was seeded on the basal channel, and the device was flipped immediately to allow the BMVECs adhere on the ECM coated PET membrane. After 5 h incubation in the hypoxic incubator, the device was flipped back to let the rest of BMVECs sit on the bottom and sides of the channel to form a capillary lumen. Cell seeded chips were kept in the hypoxic incubator for 24 h, and then the BBB Chip was fed with EC media deprived of Fgf and RA and transferred to the regular incubator (5% O2-5% CO2). On the second day of cell seeding on the microfluidic device, BBB Chips were attached to peristaltic pumps (Microprocessor controlled dispensing pump from Ismatec), and EC media was flowed through the channels with 60-100 µL/h flow rate as indicated in the study to allow the BBB Chips adjust to flow conditions; then on the third day of seeding dosing studies were performed. For TEER measurement, we seeded astrocyte, pericyte, and iPS-BMVEC on TEER chips 36 as described above, and measured the four-point impedance using a PGstat128N from Metrohm Autolab BV as previously reported 36 .
BBB opening using hypertonic solution. Hypertonic solution was generated by mixing 20% Mannitol Injection USP (1100 mOsmol/liter) and EC (280 mOsmol/liter) media in 1:3 ratio considering the dilution in the body after intra-venous or intra-arterial injection in the body. The isotonic solution was generated by mixing PBS and EC media flowed to the brain endothelial channel at 60 µl/h for 3 h, and the effluents were collected for the analysis. The detection and quantification of antibodies were performed by ELISA as described in previous report 70 . Briefly, 5 µg/mL of goat-anti-mouse antibody (Jackson ImmunoResearch) was immobilized on a high binding 96-well plate in carbonate buffer pH 9.5 for overnight at 4°C. Plate was washed with PBS with 0.1% Tween 20 for 3 times. 1% BSA in PBS was used to block the plate for 1 h at RT. Antibody samples collected from BBB Chips were incubated on the plate in the EC media for 2 h at RT. Then, an HRP-conjugated anti-mouse secondary antibody (Jackson ImmunoResearch) was used to detect the MEM75 and 13E4 antibodies on the plate. HRP enzyme on the secondary antibody was quantified using a luminescent substrate (Sigma). Standard curves for MEM75 and 13E4 antibodies was generated on the same plate to calculate the concentrations of the antibodies in the samples (Supplementary Fig. S12) . The luminescent intensity of the plates was measured using a Synergy H1 microplate reader (BioTek, USA), and the antibody concentrations in the samples from the brain and vascular channels of the BBB Chip was quantified to calculate the Papp (cm/s). 
